Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Acharya CR, et al. Among authors: potti a. JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. JAMA. 2008. Retraction in: JAMA. 2012 Feb 1;307(5):453. doi: 10.1001/jama.2012.2. PMID: 18387932 Retracted.
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Hsu DS, et al. Among authors: potti a. J Clin Oncol. 2007 Oct 1;25(28):4350-7. doi: 10.1200/JCO.2007.11.0593. J Clin Oncol. 2007. Retraction in: J Clin Oncol. 2010 Dec 10;28(35):5229. doi: 10.1200/JCO.2010.33.7311. PMID: 17906199 Retracted.
Genomic strategies for personalized cancer therapy.
Garman KS, Nevins JR, Potti A. Garman KS, et al. Among authors: potti a. Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32. doi: 10.1093/hmg/ddm184. Hum Mol Genet. 2007. PMID: 17911165 Review.
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Bonnefoi H, et al. Among authors: potti a. Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Lancet Oncol. 2007. Retraction in: Lancet Oncol. 2011 Feb;12(2):116. doi: 10.1016/S1470-2045(11)70011-0. PMID: 18024211 Retracted. Clinical Trial.
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.
Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A. Salter KH, et al. Among authors: potti a. PLoS One. 2008 Apr 2;3(4):e1908. doi: 10.1371/journal.pone.0001908. PLoS One. 2008. Retraction in: PLoS One. 2011;6(9). doi: 10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4. PMID: 18382681 Free PMC article. Retracted.
139 results